- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.05. | Dogwood Therapeutics, Inc.: Dogwood Therapeutics Announces Commencement of Halneuron Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study | 247 | GlobeNewswire (Europe) | New study to assess Halneuron pain reduction effect over three months of treatment, additional safety data to bolster planned end of Phase 2 FDA submission package Patients completing the ongoing... ► Artikel lesen | |
| 15.05. | Dogwood Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| DOGWOOD THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 14.05. | Dogwood Therapeutics GAAP EPS of -$0.15 | 1 | Seeking Alpha | ||
| 14.05. | Dogwood Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.05. | Dogwood Therapeutics, Inc.: Dogwood Therapeutics Announces First Quarter 2026 Financial Results | 1.068 | GlobeNewswire (Europe) | - Halneuron- Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026 - - FDA acceptance of SP16 Investigational New Drug Application for the treatment of Chemotherapy... ► Artikel lesen | |
| 15.04. | Dogwood Therapeutics Announces FDA Acceptance Of IND Application For SP16 | 1 | RTTNews | ||
| 15.04. | Dogwood Therapeutics receives FDA clearance for SP16 pain trial | 2 | Investing.com | ||
| 15.04. | Dogwood Therapeutics, Inc.: Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy | 193 | GlobeNewswire (Europe) | Dogwood licensed SP16 to treat cancer-related pain from partner and regulatory sponsor Serpin Pharma The SP16 Phase 1b trial fully funded by the National Cancer Institute; Patient enrollment expected... ► Artikel lesen | |
| 26.03. | Dogwood Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.03. | Dogwood Therapeutics, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 18.03. | Virios Therapeutics GAAP EPS of -$0.26 | 1 | Seeking Alpha | ||
| 18.03. | Dogwood Therapeutics, Inc.: Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results | 367 | GlobeNewswire (Europe) | ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and neuropathy... ► Artikel lesen | |
| 12.03. | Dogwood Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.01. | Dogwood Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.01. | Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron Through Phase 2b Development | 181 | GlobeNewswire (Europe) | Pricing of $12.5 Million Registered Direct Offering & Concurrent Private Placement Offerings priced at-the-market under Nasdaq rules ALPHARETTA, Ga., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics... ► Artikel lesen | |
| 08.01. | Dogwood Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 22.12.25 | Dogwood Therapeutics, Inc.: Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain | 385 | GlobeNewswire (Europe) | - Halneuron- treated patients separating from placebo on pain improvement assessment; Company expects top-line results availability in Q3 2026 - - The overall study dropout rate of ~4.4% is far below... ► Artikel lesen | |
| 02.12.25 | Dogwood Therapeutics, Inc.: Dogwood Therapeutics Files New Synthetic Halneuron Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045 | 304 | ACCESS Newswire | - New Composition of Matter Intellectual Property ("IP") Filing Centered on First-in-Class, Fully Synthetically Manufactured Halneuron-- New Synthetic Process to be Used for Phase 3 Development Provides... ► Artikel lesen | |
| 11.11.25 | Dogwood Therapeutics, Inc.: Dogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron Phase 2b Trial, Interim Sample Size Analysis on Track for December 2025 | 387 | ACCESS Newswire | - Continued low early termination rate among the first 80 study completers suggests Halneuron® and placebotreatmenthave been well tolerated ATLANTA, GEORGIA / ACCESS Newswire / November 11, 2025 / Dogwood... ► Artikel lesen | |
| 06.11.25 | Dogwood Therapeutics, Inc.: Dogwood Therapeutics Reports Third Quarter 2025 Financial Results | 413 | GlobeNewswire (Europe) | - Enrollment to date of 100 patients, with 80 patients completing treatment in the ongoing Halneuron® Phase 2b trial, prespecified interim analysis remains on track for Q4 2025 release - - Secured... ► Artikel lesen |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 79,25 | -3,29 % | Vorsicht bei BioNTech! Novo Nordisk gibt Gas! Kaufchance bei Vidac Pharma Aktie! | Kaufstimmung bei Novo Nordisk. Die Aktie des dänischen Pharmagiganten scheint den seit Sommer 2024 begonnenen Abwärtstrend zu verlassen. Anleger reagieren auf positive Meldungen. Bei Vidac Pharma ist... ► Artikel lesen | |
| EVOTEC | 5,305 | +0,47 % | EQS-NVR: Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Evotec SE
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem... ► Artikel lesen | |
| MODERNA | 39,675 | +0,18 % | Moderna, Inc.: Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting | At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of recurrence... ► Artikel lesen | |
| VALNEVA | 2,500 | -0,56 % | Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy | Original-Research: Valneva SE - von First Berlin Equity Research GmbH
28.05.2026 / 17:08 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den... ► Artikel lesen | |
| AMGEN | 283,80 | +0,30 % | Mesoblast: Während Amgen und Novo Nordisk den Biotech-Hype treiben, arbeitet dieser Zelltherapie-Player am operativen Durchbruch | ||
| NOVAVAX | 9,230 | +2,10 % | Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It | ||
| BIOGEN | 164,90 | -0,23 % | UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus | Publication adds to previously reported findings from Phase 3 PHOENYCS GO study, demonstrating statistically significant improvement in disease activity at Week 48 with dapirolizumab pegol plus standard... ► Artikel lesen | |
| BIOFRONTERA | 2,530 | +3,69 % | PTA-News: Biofrontera AG: Biofrontera berichtet über die Ergebnisse des ersten Quartals 2026 | DJ PTA-News: Biofrontera AG: BIOFRONTERA BERICHTET ÜBER DIE ERGEBNISSE DES ERSTEN QUARTALS 2026
Unternehmensmitteilung für den Kapitalmarkt
Biofrontera AG: BIOFRONTERA BERICHTET ÜBER... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 14,600 | -0,07 % | PALATIN TECHNOLOGIES INC - 8-A12B, Registration of securities | ||
| VIVOSIM LABS | 1,280 | -0,78 % | VivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales | SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,251 | -2,33 % | +36 % in wenigen Wochen! TeamViewer überzeugt Mercedes Formel-1-Team! Bald auch X und BioNxt Solutions? | Kursplus von 36 % in nur sechs Wochen! Lag die Börse bei TeamViewer völlig falsch? Ist das deutsche Software-Unternehmen am Ende gar kein KI-Verlierer, sondern ein Gewinner? Für ein abschließendes Urteil... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results | Rolling submission of Biologics License Agreement (BLA) to U.S. Food and Drug Administration (FDA) seeking ST-920 approval is in progress. Six sites activated in Phase 1/2 STAND study evaluating ST-503... ► Artikel lesen | |
| VIKING THERAPEUTICS | 27,100 | +0,74 % | Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider | ||
| INTELLIA THERAPEUTICS | 12,020 | +1,69 % | Intellia to present Phase 3 gene editing trial data at congress | ||
| TEMPUS AI | 45,500 | +0,26 % | "AI that predicts clinical outcomes?" Tempus AI in focus after ASCO data reveal |
Das Unternehmen DOGWOOD THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,700 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DOGWOOD THERAPEUTICS INC finden Sie auf Wallstreet Online.